| Ovarian cancinoma is the most lethal tumor of the female genital tract. Relatively little is known about the genetic event that induce malignant aggressive phenotypes.Therefore, it is necessary to study the molecular mechenisms and to develop a novel means of predicting and possibly treating the aggressive malignancies. Some studies indicated that activations of protooncogene c-erbB-2 are more frequently in aggressive ovarian tumors and may be associated with poor prognosis.We used an immunohistochemical technique(IHC), labelled streptavidin-biotin method (LSAB) , to study expression of c-erbB-2 in formalin-fixed paraffin-embedded tissue sections from 101 patients, which include 9 normal ovaries, 10 benign eystadeoma, 17 borderline and 65 invasive adenocarcinomas. The staining for c-erbB-2 expression was detected in benign, borderline and invasive malignant ovarion neoplasms . The positive rates of c-erbB-2 in the three groups were 49%(32/65) 35% (6/17) 10%(1/10), respectively. There is a significant differance among them. No c-erbB-2 expression in all normal ovarian epithelium and adjacent ovarian stroma were seen. Clinical correlation of the results for the 65 ovarian epithelm carcinomas revealed no statistically significant association of the intensity of erbB-2 IHC staining with stage, residual tumor size, grade or overall survival (P>0.05) We also analysed the IHC staining of c-erbB-2 expression in 17 stage I - II ovarian cancer and 17 borderline tumor. Two of six stage I -III borderline tumor in...
|
PDF Full Text Request